Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Elizabeth Greensted"'
Autor:
Vivak Parkash, Georgina Jones, Nina Martin, Morgan Steigmann, Elizabeth Greensted, Paul Kaye, Alison M. Layton, Charles J. Lacey
Publikováno v:
Research Involvement and Engagement, Vol 7, Iss 1, Pp 1-12 (2021)
Plain English summary Our research team is designing a type of research study known as a controlled human infection model (CHIM). In CHIM studies, volunteers are exposed to infections on purpose and then studied to help understand diseases. Similar e
Externí odkaz:
https://doaj.org/article/c08584d30cc84f3ab8e4c7e6c194c60d
Autor:
Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Tomas Becvar, Patrick Lypaczewski, Eli Schwartz, Elizabeth Greensted, Katrien Van Bocxlaer, Marion Pasin, Kai S. Lipinski, Vivak Parkash, Greg Matlashewski, Alison M. Layton, Charles J. Lacey, Charles L. Jaffe, Petr Volf, Paul M. Kaye
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Controlled human infection models (CHIMs) provide a pathway for accelerating vaccine development. Here, the authors describe the isolation, characterization, and GMP manufacture of a clinical Leishmania major strain to be used as a resource for CHIM
Externí odkaz:
https://doaj.org/article/ddd377d986694040985714870d5c4e1c
Autor:
Vivak Parkash, Helen Ashwin, Jovana Sadlova, Barbora Vojtkova, Georgina Jones, Nina Martin, Elizabeth Greensted, Victoria Allgar, Shaden Kamhawi, Jesus G. Valenzuela, Alison M. Layton, Charles L. Jaffe, Petr Volf, Paul M. Kaye, Charles J. N. Lacey
Publikováno v:
Wellcome Open Research, Vol 6 (2021)
Background: Leishmaniasis is a globally important yet neglected parasitic disease transmitted by phlebotomine sand flies. With new candidate vaccines in or near the clinic, a controlled human challenge model (CHIM) using natural sand fly challenge wo
Externí odkaz:
https://doaj.org/article/1b23906551454baab8079e5e896cd479
Autor:
Victoria Allgar, Petr Volf, Georgina Jones, Elizabeth Greensted, Jovana Sadlova, Helen Ashwin, Paul M. Kaye, Charles J.N. Lacey, Jesus G. Valenzuela, Barbora Vojtkova, Vivak Parkash, Charles L. Jaffe, Shaden Kamhawi, Alison M. Layton, Nina Martin
Publikováno v:
Wellcome Open Research
Background: Leishmaniasis is a globally important yet neglected parasitic disease transmitted by phlebotomine sand flies. With new candidate vaccines in or near the clinic, a controlled human challenge model (CHIM) using natural sand fly challenge wo
Autor:
Georgina Jones, Morgan Steigmann, Vivak Parkash, Alison M. Layton, Paul M. Kaye, Nina Martin, Charles J.N. Lacey, Elizabeth Greensted
Publikováno v:
Research Involvement and Engagement, Vol 7, Iss 1, Pp 1-12 (2021)
Research Involvement and Engagement
Research Involvement and Engagement
Background A controlled human infection model (CHIM) involves deliberate exposure of volunteers to pathogens to assess their response to new therapies at an early stage of development. We show here how we used public involvement to help shape the des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e56c8242ceaa97f6bb9473c1cb1c555e
https://eprints.whiterose.ac.uk/179771/1/s40900_021_00277_y.pdf
https://eprints.whiterose.ac.uk/179771/1/s40900_021_00277_y.pdf
Autor:
Greg Matlashewski, Petr Volf, Elizabeth Greensted, Tomas Becvar, Vivak Parkash, Patrick Lypaczewski, Eli Schwartz, Charles J.N. Lacey, Marion Pasin, Jovana Sadlova, Paul M. Kaye, Helen Ashwin, Kai S. Lipinski, Charles L. Jaffe, Katrien Van Bocxlaer, Alison M. Layton, Barbora Vojtkova
Publikováno v:
Nature Communications, Vol 12, Iss 1, Pp 1-12 (2021)
Nature Communications
Nature Communications
Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be progressed into human studies significantly limits progress in vaccine
Autor:
Elizabeth Greensted, Paul M. Kaye, Petr Volf, Helen Ashwin, Eli Schwartz, Barbora Vojtkova, Charles J.N. Lacey, Marion Pasin, Tomas Becvar, Alison M. Layton, Kai S. Lipinski, Greg Matlashewski, Vivak Parkash, Charles L. Jaffe, Patrick Lypaczewski, Katrien Van Bocxlaer, Jovana Sadlova
Leishmaniasis is widely regarded as a vaccine-preventable disease, but the costs required to reach pivotal Phase 3 studies and uncertainty about which candidate vaccines should be progressed into human studies significantly limits progress in vaccine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::26829e33325cdfe420eb15ac1b434281
https://doi.org/10.1101/2020.08.12.245936
https://doi.org/10.1101/2020.08.12.245936